Skip to content

The effect of emotional self- disclosure on disease activity, health status and sexual function in women with rheumatoid arthritis

The effect of emotional self- disclosure on disease activity, health status and sexual function in women with rheumatoid arthritis in comparison with control group

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110629006917N6
Enrollment
72
Registered
2022-08-19
Start date
2022-07-30
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: First, the participants will complete questionnaires including demographic characteristic, clinical status of the disease, FSFI (Female Sexual Function Index) and A

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age 18-45 years At least 6 months have passed since the diagnosis of the disease Able to read and write in Farsi Living with a spouse at the time of the study Having sexual activity at least once in the last 4 weeks Monogamous husband Living in Tehran

Exclusion criteria

Exclusion criteria: Suffering from another chronic disease other than Rheumatoid arthritis in research units Current pregnancy or breastfeeding and less than 6 months have passed since the last delivery According to the patient, the occurrence of a stressful incident 3 months before the intervention Suffering from major medical diseases affecting sexual relations (Diabetes, history of psychiatric disorders such as severe Depression, Psychosis, Bipolar disorder, substance abuse) according to the patient' statement and the contents of his file Taking drugs affecting sexual performance Sexual disorders under treatment in women or husbands (desire phase disorder, arousal phase disorder, orgasm disorder, sexual pain disorders)

Design outcomes

Primary

MeasureTime frame
Disease activity. Timepoint: In each of the two test and control groups before the start of the study and 8 weeks after the intervention. Method of measurement: In both groups, it will be measured by a rheumatology specialist using the 28-DAS tool.;Health status. Timepoint: The measurement of this variable will be done before the start of the study, immediately and 8 weeks after the end of the intervention. Method of measurement: Completing the health status questionnaire (AIMS2-SF) by the participants.;Sexual function. Timepoint: The measurement of this variable in all 6 areas will be done before the start of the study, immediately and 8 weeks after the end of the intervention. Method of measurement: Completion of the Female Sexual Function Index (FSFI) questionnaire by the participants.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Ashrafpour

Iran University of Medical Sciences

elnazashrafpour@gmail.com+98 21 8888 2886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026